Mononuclear Therapeutics Limited
@monotx.com
Mononuclear Therapeutics (MonoTx ®) Limited collects, processes, tests and banks human umbilical cord blood (UCB) and components for research and to treat disease. The MonoTx ® cord blood bank complies with international standards for treating hematologic disorders. MonoTx ® cord blood bank is AABB accredited and FDA registered. MonoTx ® is also a member of World Marrow Donation Association (WMDA) for release of cord blood cells for hematopoietic diseases treatment.
Mononuclear Therapeutics Limited's Company Logos
Mononuclear Therapeutics Limited's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#104791
Torea Bay
16, 71, 145
214, 80, 32
89, 51, 0, 43
#FFFFFF
White
255, 255, 255
0, 0, 100
0, 0, 0, 0
#541E50
Tawny Port
84, 30, 80
304, 47, 22
0, 64, 5, 67
About Mononuclear Therapeutics Limited
MonoTx™ is a Biotechnology and Translational Medicine company that focuses on therapies derived from umbilical cord blood and tissue. Their main area of expertise lies in neurological disorders such as chronic spinal cord injury (SCI), chronic stroke, and age-related macular degeneration (AMD). These conditions affect millions of people worldwide.
The company works closely with renowned research institutions in the USA and Hong Kong to conduct research and development. Since its establishment in Hong Kong in 2016, MonoTx has been collecting, processing, and banking cord blood to build inventories of mononuclear cells for research and future therapeutic applications. Their efforts have led to the establishment of the first public cord blood mononuclear cell bank in Hong Kong, which is internationally accredited and registered with several health organizations.
With a management team comprised of experts in the field, MonoTx is committed to advancing the field of cellular therapy and providing high-quality treatment options for patients in need
Company type
Privately Held
Year founded
2016
Company size
11-50 employees
